Albach FN, Minopoulou I, Wilhelm A, Biesen R, Kleyer A, Wiebe E, Fleischmann A, Frick M, Damm F, Gogolok J, Serve S, Locher BN, Borie D, Casteleyn V, Siegert E, Dörner T, Alexander T, Furth C, Zernicke J, Movassaghi K, Hütter-Krönke ML, Schrezenmeier E, Schneider U, Bullinger L, Krönke G, Penack O, Simon D. Targeting autoimmunity with CD19-CAR T cell therapy: efficacy and seroconversion in diffuse systemic sclerosis and rheumatoid arthritis. Rheumatology (Oxford). 2025 Feb 10:keaf077. doi: 10.1093/rheumatology/keaf077. Epub ahead of print. PMID: 39928370.

Braun LM, Giesler S, Andrieux G, Riemer R, Talvard-Balland N, Duquesne S, Rückert T, Unger S, Kreutmair S, Zwick M, Follo M, Hartmann A, Osswald N, Melchinger W, Chapman S, Hutchinson JA, Haferkamp S, Torster L, Kött J, Gebhardt C, Hellwig D, Karantzelis N, Wallrabenstein T, Lowinus T, Yücel M, Brehm N, Rawluk J, Pfeifer D, Bronsert P, Rogg M, Mattern S, Heikenwälder M, Fusco S, Malek NP, Singer S, Schmitt-Graeff A, Ceteci F, Greten FR, Blazar BR, Boerries M, Köhler N, Duyster J, Ihorst G, Lassmann S, Keye P, Minguet S, Schadendorf D, Ugurel S, Rafei-Shamsabadi D, Thimme R, Hasselblatt P, Bengsch B, Schell C, Pearce EL, Meiss F, Becher B, Funke-Lorenz C, Placke JM, Apostolova P, Zeiser R. Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity. Cancer Cell. 2025 Feb 10;43(2):269-291.e19. doi: 10.1016/j.ccell.2025.01.004. PMID: 39933899.

Cho HR, Isfort S, Kricheldorf K, Stegelmann F, Klausmann M, Heidel FH , Griesshammer M, Schulz H, Hochhaus A, Göthert J, Schlag R, Hollburg W, Teichmann L, Sockel K, Wilop S, Gezer D, Kirschner M, Döhner K , Brümmendorf TH, Koschmieder S; German Study Group for Myeloproliferative Neoplasms (GSG‐MPN). Mitigation of atrial fibrillation-related complications with antithrombotic and cytoreductive therapy in patients with Myeloproliferative Neoplasms: Implications from the GSG-MPN bioregistry.  Hemasphere. 2025 Mar 17;9(3):e70090. doi: 10.1002/hem3.70090. eCollection 2025 Mar. PMID:40098896. [IF 11.9].

Cocciardi S, Saadati M, Weiß N, Späth D, Kapp-Schwoerer S, Schneider I, Meid A, Gaidzik VI, Skambraks S, Fiedler W, Kühn MWM, Germing U, Mayer KT, Lübbert M, Papaemmanuil E, Thol F, Heuser M, Ganser A, Bullinger L, Benner A, Döhner H, Döhner K. Impact of myelodysplasia-related and additional gene mutations in intensively treated patients with NPM1-mutated AML. Hemasphere. 2025 Jan 15;9(1):e70060. doi: 10.1002/hem3.70060. PMID: 39816531; PMCID: PMC11733593.

Giesler S, Riemer R, Lowinus T, Zeiser R. Immune-mediated colitis after immune checkpoint inhibitor therapy. Trends Mol Med. 2025 Mar;31(3):265-280. doi: 10.1016/j.molmed.2024.09.009. Epub 2024 Oct 29. PMID: 39477757.

Harrison CN, Ross DM, Fogliatto LM, Foltz L, Busque L, Xiao Z, Heidel FH , Koehler M, Palumbo GA, Breccia M, Komatsu N, Kirito K, Xicoy Cirici B, Martinez-Lopez J, Rovo A, Petruk C, Bobirca C, Mirams L, McMillan A, Harper G, Kiladjian JJ. Patient and physician perceptions regarding treatment expectations and symptomatology in polycythemia vera: Insights from the Landmark 2.0 global health survey.Hemasphere. 2025 Mar 24;9(3):e70106. doi: 10.1002/hem3.70106. eCollection 2025 Mar. PMID: 40130070. [IF 11.9].

Ho NHJG, Talvard-Balland N, Köhler N, Zeiser R. Immune Escape of Acute Myeloid Leukemia after Transplantation. Blood Cancer Discov. 2025 Mar 28:OF1-OF14. doi: 10.1158/2643-3230.BCD-24-0063. Epub ahead of print. PMID: 40168448.

Junkuhn C, Schiele P, Walter AL, Hamm F, Obermayer B, Busch D, Stroux A, Frick M, Penack O, Damm F, Polansky J, Bullinger L, Künkele A, Frentsch M, Na IK. Prior chemotherapy deteriorates T-cell quality for CAR T-cell therapy in B-cell non-Hodgkin’s lymphoma. J Immunother Cancer. 2025 Apr 9;13(4):e010709. doi: 10.1136/jitc-2024-010709. PMID: 40210237.

Manz K, Heidel FH , Koschmieder S, Schlag R, Lipke J, Stegelmann F, Griesshammer M, Klausmann M, Crodel C, Hochhaus A, Schulz H, Göthert JR, Al-Ali H, Becker H, Reiter A, Beutel G, Kricheldorf K, Brümmendorf TH, Hoffmann W,  Döhner K, Isfort S; German Study Group for Myeloproliferative Neoplasms (GSG-MPN). Comparison of recognition of symptom burden in MPN between patient- and physician-reported assessment – an intraindividual analysis by the German Study Group for MPN (GSG-MPN.  Leukemia. 2025 Feb 25. doi: 10.1038/s41375-025-02524-7. Online ahead of print. PMID: 40000843 [IF 12.8].

Minopoulou I, Wilhelm A, Albach F, Kleyer A, Wiebe E, Schallenberg S, Fleischmann A, Frick M, Damm F, Gogolok J, Serve S, Locher BN, Borie D, Casteleyn V, Biesen R, Dörner T, Alexander T, Zernicke J, Movassaghi K, Hütter-Krönke ML, Schrezenmeier E, Schreiber A, Schneider U, Bullinger L, Krönke G, Penack O, Simon D. Anti-CD19 CAR T cell therapy induces antibody seroconversion and complete B cell depletion in the bone marrow of a therapy-refractory patient with ANCA-associated vasculitis. Ann Rheum Dis. 2025 Mar;84(3):e4-e7. doi: 10.1016/j.ard.2025.01.008. Epub 2025 Jan 31. PMID: 39893102.

Perner F, Pahl HL, Zeiser R,  Heidel FH. Malignant JAK-signaling: at the interface of inflammation and malignant transformation.  Leukemia. 2025 Mar 26. doi: 10.1038/s41375-025-02569-8. Online ahead of print. PMID: 40140631. [IF 12.8].

Perner F, Berg T, Sasca D, Mersiowsky SL, Gadrey JY, Thomas J, Kühn MWM, Lübbert M. Therapeutic targeting of chromatin alterations in leukemia and solid tumors. Int J Cancer. 2025 Apr 3. doi: 10.1002/ijc.35389. Epub ahead of print. PMID: 40181550.

Perner F, Gadrey JY, Armstrong SA, Kühn MWM. Targeting the Menin-KMT2A interaction in leukemia: Lessons learned and future directions. Int J Cancer. 2025 Jan 30. doi: 10.1002/ijc.35332. Epub ahead of print. PMID: 39887730.

Shahswar R, Gabdoulline R, Krueger K, Wichmann M, Götze KS, Braitsch K, Meggendorfer M, Schmalbrock L,  Bullinger L, Modemann F, Fiedler W, Krauter J, Kaun S, Rotermund S, Voß A, Behrens YL, Bergmann AK, Koller E, Beutel G, Thol F,  Heidel F, Heuser M. A novel prognostic risk model for patients with refractory/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agents.  Leukemia. 2025 Jan 8. doi: 10.1038/s41375-024-02501-6. Online ahead of print. PMID: 39779979. [IF 12.8].

Sollier E, Riedel A, Toprak UH, Wierzbinska JA, Weichenhan D, Schmid JP, Hakobyan M, Touzart A, Jahn E, Vick B, Brown-Burke F, Kelly K, Kelekci S, Pejkovska A, Goyal A, Bähr M, Breuer K, Chen MM, Llamazares-Prada M, Hartmann M, Schönung M, Correia N, Trumpp A, Abdullah Y, Klingmüller U, Mughal SS, Brors B, Westermann F, Ulrich E, Autry RJ, Schlesner M, Vosberg S, Herold T, Greif PA, Pfeifer D, Lübbert M, Fischer T, Heidel FH, Gebhard G, Walter W, Haferlach T, Eisfeld AK, Mrózek K, Nicolet D, Bullinger L, Smeenk L, Erpelinck-Verschueren C, Mulet-Lazaro R, Delwel R, Ernst A, Scherer M, Lutsik P, Jeremias I, Döhner K, Döhner H, Lipka DB, Plass C. Enhancer hijacking discovery in acute myeloid leukemia by pyjacker identifies MNX1 activation via deletion 7q. Blood Cancer Discov. 2025 Mar 31. doi: 10.1158/2643-3230.BCD-24-0278. Epub ahead of print. PMID: 40162972.

Voso MT, Guarnera L, Lehmann S, Döhner K, Döhner H, Platzbecker U, Russell N, Dillon R, Thomas I, Ossenkoppele G, Haferlach T, Vignetti M, La Sala E, Piciocchi A, Fazi P, Ramiro AV, Giménez LT, Gurnari C, Bullinger L, Hernández-Rivas JM. Acute promyelocytic leukemia: long-term outcomes from the HARMONY project. Blood. 2025 Jan 9;145(2):234-243. doi: 10.1182/blood.2024026186. PMID: 39504485.

Zähringer A, Morgado I, Erny D, Ingelfinger F, Gawron J, Chatterjee S, Wenger V, Schmidt D, Schwöbel LF, Adams RC, Langenbach M, Hartmann A, Osswald N, Wolf J, Schlunck G, Briquez PS, Grueter K, Ruess DA, Frew I, Burk AC, Holzmüller V, Grimbacher B, Michonneau D, Andrieux G, Socié G, Kolter J, Börries M, Follo M, Blaeschke F, Sevenich L, Prinz M, Zeiser R, Vinnakota JM. AhR activation mitigates graft-versus-host disease of the central nervous system by reducing microglial NF-κB signaling. Blood Adv. 2025 Mar 31:bloodadvances.2024015000. doi: 10.1182/bloodadvances.2024015000. Epub ahead of print. PMID: 40163754.

Arends CM, Kopp K, Hablesreiter R, Estrada N, Christen F, Moll UM, Zeillinger R, Schmitt WD, Sehouli J, Kulbe H, Fleischmann M, Ray-Coquard I, Zeimet A, Raspagliesi F, Zamagni C, Vergote I, Lorusso D, Concin N, Bullinger L, Braicu EI, Damm F. Correction: Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer. Leukemia. 2024 Jun;38(6):1440. doi: 10.1038/s41375-024-02274-y. Erratum for: Leukemia. 2024 Jun;38(6):1378-1389. doi: 10.1038/s41375-024-02253-3. PMID: 38714878; PMCID: PMC11147748.

Bruedigam C, Porter AH, Song A, Vroeg In de Wei G, Stoll T, Straube J, Cooper L, Cheng G, Kahl VFS, Sobinoff AP, Ling VY, Jebaraj BMC, Janardhanan Y, Haldar R, Bray LJ, Bullinger L, Heidel FH, Kennedy GA, Hill MM, Pickett HA, Abdel-Wahab O, Hartel G, Lane SW. Imetelstat-mediated alterations in fatty acid metabolism to induce ferroptosis as a therapeutic strategy for acute myeloid leukemia. Nat Cancer. 2024 Jan;5(1):47-65. doi: 10.1038/s43018-023-00653-5. Epub 2023 Oct 30. PMID: 37904045; PMCID: PMC10824665.

Griesshammer M, Al-Ali HK, Eckardt JN, Fiegl M, Göthert J, Jentsch-Ullrich K, Koschmieder S, Kvasnicka HM, Reiter A, Schmidt B, Heidel FH. How I diagnose and treat patients in the pre-fibrotic phase of primary myelofibrosis (pre-PMF) – practical approaches of a German expert panel discussion in 2024. Ann Hematol. 2025 Jan 31. doi: 10.1007/s00277-025-06191-7. Online ahead of print. PMID: 39888352. [IF 3.5].

Halik A, Tilgner M, Silva P, Estrada N, Altwasser R, Jahn E, Heuser M, Hou HA, Pratcorona M, Hills RK, Metzeler KH, Fenwarth L, Dolnik A, Terre C, Kopp K, Blau O, Szyska M, Christen F, Krönke J, Vasseur L, Löwenberg B, Esteve J, Valk PJM, Duchmann M, Chou WC, Linch DC, Döhner H, Gale RE, Döhner K, Bullinger L, Yoshida K, Damm F. Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients. J Hematol Oncol. 2024 Aug 19;17(1):70. doi: 10.1186/s13045-024-01590-1. PMID: 39160538; PMCID: PMC11331663.

Heikamp EB, Martucci C, Henrich JA, Neel DS, Mahendra-Rajah S, Rice H, Wenge DV, Perner F, Wen Y, Hatton C, Armstrong SA. NUP98 fusion proteins and KMT2A-MENIN antagonize PRC1.1 to drive gene expression in AML. Cell Rep. 2024 Nov 26;43(11):114901. doi: 10.1016/j.celrep.2024.114901. Epub 2024 Oct 30. PMID: 39475509; PMCID: PMC11780541.

Hernández-Sánchez A, González T, Sobas M, Sträng E, Castellani G, Abáigar M, Valk PJM, Villaverde Ramiro Á, Benner A, Metzeler KH, Azibeiro R, Tettero JM, Martínez-López J, Pratcorona M, Martínez Elicegui J, Mills KI, Thiede C, Sanz G, Döhner K, Heuser M, Haferlach T, Turki AT, Reinhardt D, Schulze-Rath R, Barbus M, Hernández-Rivas JM, Huntly B, Ossenkoppele G, Döhner H, Bullinger L. Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications – a HARMONY study. Leukemia. 2024 Sep;38(9):1929-1937. doi: 10.1038/s41375-024-02333-4. Epub 2024 Jul 4. PMID: 38965370; PMCID: PMC11347382.

Isfort S, von Bubnoff N, Al-Ali HK, Becker H, Götze T, le Coutre P, Griesshammer M, Moskwa C, Wohn L, Riedel J, Palandri F, Manz K, Hochhaus A, Döhner K, Heidel FH. FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN). Ann Hematol. 2024 Aug;103(8):2775-2785. doi: 10.1007/s00277-024-05867-w. Epub 2024 Jul 5. PMID: 38967662; PMCID: PMC11283433.

Kiladjian JJ, Marin FF, Al-Ali HK, Alvarez-Larrán A, Beggiato E, Bieniaszewska M, Breccia M, Buxhofer-Ausch V, Cerna O, Crisan AM, Danaila CD, De Stefano V, Döhner K, Empson V, Gora-Tybor J, Griesshammer M, Grosicki S, Guglielmelli P, García-Gutierrez V, Heidel FH, Illés A, Tomuleasa C, James C, Koschmieder S, Krauth MT, Krejcy K, Lazaroiu MC, Mayer J, Nagy ZG, Nicolini FE, Palandri F, Pappa V, Reiter AJ, Sacha T, Schlager S, Schmidt S, Terpos E, Unger M, Wölfler A, Cirici BX, Klade C. ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options. Ann Hematol. 2024 Jul;103(7):2299-2310. doi: 10.1007/s00277-024-05665-4. Epub 2024 Mar 4. PMID: 38438627; PMCID: PMC11224110.

Krumbholz M, Dolnik A, Sträng E, Ghete T, Skambraks S, Hutter S, Simonis A, Stegelmann F, Suttorp M, Horn AHC, Sticht H, Haferlach T, Bullinger L, Metzler M. A high proportion of germline variants in pediatric chronic myeloid leukemia. Mol Cancer. 2024 Sep 26;23(1):206. doi: 10.1186/s12943-024-02109-5. PMID: 39327604; PMCID: PMC11426096.

Ling VY, Heidel FH , Bywater MJ. Pathogenesis and management of high molecular risk myeloproliferative neoplasms. Haematologica. 2024 Dec 5. doi: 10.3324/haematol.2023.283987. Online ahead of print. PMID: 39633552

Noerenberg D, Briest F, Hennch C, Yoshida K, Hablesreiter R, Takeuchi Y, Ueno H, Staiger AM, Ziepert M, Asmar F, Locher BN, Toth E, Weber T, Amini RM, Klapper W, Bouzani M, Poeschel V, Rosenwald A, Held G, Campo E, Ishaque N, Stamatopoulos K, Kanellis G, Anagnostopoulos I, Bullinger L, Goldschmidt N, Zinzani PL, Bödör C, Rosenquist R, Vassilakopoulos TP, Ott G, Ogawa S, Damm F. Genetic Characterization of Primary Mediastinal B-Cell Lymphoma: Pathogenesis and Patient Outcomes. J Clin Oncol. 2024 Feb 1;42(4):452-466. doi: 10.1200/JCO.23.01053. Epub 2023 Dec 6. PMID: 38055913.

Rücker FG, Bullinger L, Cocciardi S, Skambraks S, Luck TJ, Weber D, Krzykalla J, Pozek E, Schneider I, Corbacioglu A, Gaidzik VI, Meid A, Aicher S, Stegelmann F, Schrade A, Theis F, Fiedler W, Salih HR, Wulf G, Salwender H, Schroeder T, Götze KS, Kühn MWM, Lübbert M, Schlenk RF, Benner A, Thol F, Heuser M, Ganser A, Döhner H, Döhner K. Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin. Blood Adv. 2024 Dec 10;8(23):6067-6080. doi: 10.1182/bloodadvances.2024013758. PMID: 39348668; PMCID: PMC11652759.

Rücker FG, Corbacioglu A, Krzykalla J, Cocciardi S, Lengerke C, Germing U, Wulf G, Samra MA, Teichmann LL, Lübbert M, Kühn MWM, Bentz M, Westermann J, Bullinger L, Gaidzik VI, Meid A, Aicher S, Stegelmann F, Weber D, Schrade A, Thol F, Heuser M, Ganser A, Benner A, Döhner H, Döhner K; German‐Austrian Acute Myeloid Leukemia Study Group (AMLSG). Refinement of the prognostic impact of somatic CEBPA bZIP domain mutations in acute myeloid leukemia: Results of the AML Study Group (AMLSG). Hemasphere. 2024 Jul 15;8(7):e123. doi: 10.1002/hem3.123. PMID: 39011127; PMCID: PMC11247273.

Scharr MV, Damm F, Krahl P, Dieper A, Veltsista PD, Hansch A, Beck M, Gerster D, Giovannelli AC, Bullinger L, Zips D, Ghadjar P. Review of preclinical data on hyperthermia treatment in lymphomas and its potential for clinical application. Int J Hyperthermia. 2024;41(1):2418427. doi: 10.1080/02656736.2024.2418427. Epub 2024 Nov 3. PMID: 39489511.

Schmidt D, Endres C, Hoefflin R, Andrieux G, Zwick M, Karantzelis N, Staehle HF, Vinnakota JM, Duquesne S, Mozaffari Jovein M, Pfeifer D, Becker H, Blazar BR, Zähringer A, Duyster J, Brummer T, Boerries M, Baumeister J, Shoumariyeh K, Li J, Green AR, Heidel FH, Tirosh I, Pahl HL, Leimkühler N, Köhler N, de Toledo MAS, Koschmieder S, Zeiser R. Oncogenic Calreticulin Induces Immune Escape by Stimulating TGF-βExpression and Regulatory T Cell Expansion in the Bone Marrow Microenvironment. Cancer Res. 2024 Jun 17. doi: 10.1158/0008-5472.CAN-23-3553. Online ahead of print. PMID: 38885318. [IF 12.701].

Sobas MA, Turki AT, Ramiro AV, Hernández-Sánchez A, Elicegui JM, González T, Melchor RA, Abáigar M, Tur L, Dall’Olio D, Sträng E, Tettero JM, Castellani G, Benner A, Döhner K, Thiede C, Metzeler KH, Haferlach T, Damm F, Ayala R, Martínez-López J, Mills KI, Sierra J, Lehmann S, Porta MGD, Mayer J, Reinhardt D, Medina RV, Schulze-Rath R, Barbus M, Hernández-Rivas JM, Huntly BJP, Ossenkoppele G, Döhner H, Bullinger L. Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance. Haematologica. 2024 Nov 7. doi: 10.3324/haematol.2024.285805. Epub ahead of print. PMID: 39506894.

Talvard-Balland N, Braun LM, Dixon KO, Zwick M, Engel H, Hartmann A, Duquesne S, Penter L, Andrieux G, Rindlisbacher L, Acerbis A, Ehmann J, Köllerer C, Ansuinelli M, Rettig A, Moschallski K, Apostolova P, Brummer T, Illert AL, Schramm MA, Cheng Y, Köttgen A, Duyster J, Menssen HD, Ritz J, Blazar BR, Boerries M, Schmitt-Gräff A, Sariipek N, Van Galen P, Buescher JM, Cabezas-Wallscheid N, Pahl HL, Pearce EL, Soiffer RJ, Wu CJ, Vago L, Becher B, Köhler N, Wertheimer T, Kuchroo VK, Zeiser R. Oncogene-induced TIM-3 ligand expression dictates susceptibility to anti-TIM-3 therapy in mice. J Clin Invest. 2024 Jun 25;134(16):e177460. doi: 10.1172/JCI177460. PMID: 38916965; PMCID: PMC11324309.

Tefferi A, Barosi G, Passamonti F, Hernandez-Boluda JC, Bose P, Döhner K, Ellis M, Gangat N, Garcia JS, Gisslinger H, Gotlib J, Guglielmelli P, Gupta V, Harrison C, Hexner EO, Hobbs GS, Kiladjian JJ, Koschmieder S, Kroger N, Kuykendall AT, Loscocco GG, Mascarenhas J, Masarova L, Mesa R, Mora B, Odenike O, Oh ST, Pardanani A, Patel A, Pemmaraju N, Rambaldi A, Rampal R, Sirhan S, Szuber N, Talpaz M, Vachhani PJ, Vannucchi AM, Barbui T. Proposals for revised International Working Group-European LeukemiaNet criteria for anemia response in myelofibrosis. Blood. 2024 Oct 24;144(17):1813-1820. doi: 10.1182/blood.2024025802. PMID: 39116296.

Bahrami, E., et al. (2023). Combined proteomics and CRISPR‒Cas9 screens in PDX identify ADAM10 as essential for leukemia in vivo. Mol Cancer 22, 107. 10.1186/s12943-023-01803-0.

Dill, V., et al. (2023). Elevated RIPK3 correlates with disease burden in myelofibrosis. Blood Adv 7, 1219- 1224. 10.1182/bloodadvances.2021006838

Issa, G.C., et al. (2023). The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature 615, 920-924. 10.1038/s41586-023-05812-3.

Jaeger, A., et al. (2023). Activated granulocytes and inflammatory cytokine signaling drive T-cell lymphoma progression and disease symptoms. Blood 141, 2824-2840. 10.1182/blood.2022015653.

Klever, M.K., et al. (2023). AML with complex karyotype: extreme genomic complexity revealed by combined long-read sequencing and Hi-C technology. Blood Adv. 10.1182/bloodadvances.2023010887.

Lichtner, G., et al. (2023). Interoperable, Domain-Specific Extensions for the German Corona Consensus (GECCO) COVID-19 Research Data Set Using an Interdisciplinary, Consensus-Based Workflow: Data Set Development Study. JMIR Med Inform 11, e45496. 10.2196/45496.

Naher, A.F., et al. (2023). Secondary data for global health digitalisation. Lancet Digit Health 5, e93-e101. 10.1016/S2589-7500(22)00195-9.

Perner, F., et al. (2023). MEN1 mutations mediate clinical resistance to menin inhibition. Nature 615, 913-919. 10.1038/s41586-023-05755-9.

Stegelmann, F. et al. (2023) Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α: a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN). Leukemia 37, 924-928. https://doi.org:10.1038/s41375-023-01837-9

Stellmach, C., et al. (2023). Creation of a structured molecular genomics report for Germany as a local adaption of HL7’s Genomic Reporting Implementation Guide. J Am Med Inform Assoc 30, 1179-1189. 10.1093/jamia/ocad061.

Aubrey, B.J., et al. (2022). IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia. Nat Cancer 3, 595-613. 10.1038/s43018-022-00366-1.

Cerisoli, F., et al. (2022). Building a Healthcare Alliance for Resourceful Medicine Offensive Against Neoplasms in Hematology Added Value Framework for Hematologic Malignancies: A Comparative Analysis of Existing Tools. Value Health 25, 1760-1767. 10.1016/j.jval.2022.04.1729

Ernst, P., et al. (2022). Histone demethylase KDM4C is a functional dependency in JAK2-mutated neoplasms. Leukemia 36, 1843-1849. 10.1038/s41375-022-01611-3.

Hernandez-Malmierca, P., et al. (2022). Antigen presentation safeguards the integrity of the hematopoietic stem cell pool. Cell Stem Cell 29, 760-775 e710. 10.1016/j.stem.2022.04.007.

Jacobsen, J.O.B., et al. (2022). The GA4GH Phenopacket schema defines a computable representation of clinical data. Nat Biotechnol 40, 817-820. 10.1038/s41587-022-01357-4.

Jahn, N., et al. (2022). Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial. Leukemia 36, 2218-2227. 10.1038/s41375-022-01650-w

Jayavelu, A.K., et al. (2022). The proteogenomic subtypes of acute myeloid leukemia. Cancer Cell 40, 301- 317 e312. 10.1016/j.ccell.2022.02.006.

Krenn, P. W., Montanez, E., Costell, M. & Fässler, R. Integrins, anchors and signal transducers of hematopoietic stem cells during development and in adulthood. Curr Top Dev Biol 149, 203-261 (2022). https://doi.org:10.1016/bs.ctdb.2022.02.009

Olsen, S.N., et al. (2022). MLL::AF9 degradation induces rapid changes in transcriptional elongation and subsequent loss of an active chromatin landscape. Mol Cell 82, 1140-1155 e1111. 10.1016/j.molcel.2022.02.013.

Rinaldi, E., et al. (2022). Harmonization and standardization of data for a pan-European cohort on SARSCoV-2 pandemic. NPJ Digit Med 5, 75. 10.1038/s41746-022-00620-x

Perner, F., et al. (2022). YBX1 mediates translation of oncogenic transcripts to control cell competition in AML. Leukemia 36, 426-437. 10.1038/s41375-021-01393-0

Schnoeder, T.M., et al. (2022). PLCG1 is required for AML1-ETO leukemia stem cell self-renewal. Blood 139, 1080-1097. 10.1182/blood.2021012778.

Vorisek, C.N., et al. (2022). Fast Healthcare Interoperability Resources (FHIR) for Interoperability in Health Research: Systematic Review. JMIR Med Inform 10, e35724. 10.2196/35724.

Baumeister, J., Chatain, N., Sofias, A. M., Lammers, T. & Koschmieder, S. (2021) Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives. Cells 10. https://doi.org:10.3390/cells10123551

Dolnik, A., et al. (2021). Genome Sequencing in Myeloid Cancers. N Engl J Med 384, e106. 10.1056/NEJMc2106014.

Haider, N., et al. (2021). Signaling defects associated with insulin resistance in nondiabetic and diabetic individuals and modification by sex. J Clin Invest 131. 10.1172/JCI151818.

Heidel, F.H., et al. (2021). The Genomic Landscape of Myeloid Malignancies: Options for Pan-myeloid Therapies? Hemasphere 5, e537. 10.1097/HS9.0000000000000537.

Heikamp, E.B., et al. (2021). The Menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML. Blood. 10.1182/blood.2021012806.

Leimkühler, N. B. et al. (2021) Heterogeneous bone-marrow stromal progenitors drive myelofibrosis via a druggable alarmin axis. Cell Stem Cell 28, 637-652.e638. https://doi.org:10.1016/j.stem.2020.11.004

Lux, S., et al. (2021). Deregulated expression of circular RNAs in acute myeloid leukemia. Blood Adv 5, 1490-1503. 10.1182/bloodadvances.2020003230.

Schmalbrock, L.K., et al. (2021). Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin. Blood 137, 3093-3104. 10.1182/blood.2020007626.

Serramito-Gomez, I., et al. (2021). NEMHESYS-European Perspective on the Implementation of Nextgeneration Sequencing Into Clinical Diagnostics. Hemasphere 5, e541. 10.1097/HS9.0000000000000541.

Olschok, K. et al. (2021) CALR frameshift mutations in MPN patient-derived iPSCs accelerate maturation of megakaryocytes. Stem Cell Reports 16, 2768-2783. https://doi.org:10.1016/j.stemcr.2021.09.019

Zeiser, R., et al. (2021). Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease. N Engl J Med 385, 228-238. 10.1056/NEJMoa2033122.

Batista, T.M., et al. (2020). A Cell-Autonomous Signature of Dysregulated Protein Phosphorylation Underlies Muscle Insulin Resistance in Type 2 Diabetes. Cell Metab 32, 844-859 e845. 10.1016/j.cmet.2020.08.007.

Hamarsheh, S., et al. (2020). Oncogenic Kras(G12D) causes myeloproliferation via NLRP3 inflammasome activation. Nat Commun 11, 1659. 10.1038/s41467-020-15497-1.

Jahn, N., et al. (2020). Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication. Blood Adv 4, 6342-6352. 10.1182/bloodadvances.2020002673.

Jayavelu, A.K., et al. (2020). Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms. Nature 588, 157-163. 10.1038/s41586-020-2968-3.

Kapp-Schwoerer, S., et al. (2020). Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial. Blood 136, 3041-3050. 10.1182/blood.2020005998.

Krenn, P. W., Koschmieder, S. & Fässler, R. (2020) Kindlin-3 loss curbs chronic myeloid leukemia in mice by mobilizing leukemic stem cells from protective bone marrow niches. Proc Natl Acad Sci U S A 117, 24326- 24335. https://doi.org:10.1073/pnas.2009078117

Lang, K.M., et al. (2020). Core outcome set measurement for future clinical trials in acute myeloid leukemia: the HARMONY study protocol using a multi-stakeholder consensus-based Delphi process and a final consensus meeting. Trials 21, 437. 10.1186/s13063-020-04384-1.

Perner, F., et al. (2020). Targeting Chromatin Complexes in Myeloid Malignancies and Beyond: From Basic Mechanisms to Clinical Innovation. Cells 9. 10.3390/cells9122721.

Radke, T.F., et al. (2020). Evaluation of current genetic testing reports in German-speaking countries with regard to secondary use and future electronic implementation. Eur J Hum Genet 28, 558-566. 10.1038/s41431-020-0586-z.

Reich, D., et al. (2020). SHP1 regulates a STAT6-ITGB3 axis in FLT3ITD-positive AML cells. Leukemia 34, 1444-1449. 10.1038/s41375-019-0676-5.

Uckelmann, H.J., et al. (2020). Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia. Science 367, 586-590. 10.1126/science.aax5863.

Uhl, F.M., et al. (2020). Metabolic reprogramming of donor T cells enhances graft-versus-leukemia effects in mice and humans. Sci Transl Med 12. 10.1126/scitranslmed.abb8969.

Zeiser, R., et al. (2020). Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease. N Engl J Med 382, 1800-1810. 10.1056/NEJMoa1917635.

Cocciardi, S., et al. (2019). Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation. Nat Commun 10, 2031. 10.1038/s41467-019-09745-2.

Czech, J. et al. (2019) JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation. Leukemia 33, 995-1010. https://doi.org:10.1038/s41375-018-0295-6

Jutzi, J.S., et al. (2019). Altered NFE2 activity predisposes to leukemic transformation and myelosarcoma with AML-specific aberrations. Blood 133, 1766-1777. 10.1182/blood-2018-09-875047.

Krivtsov, A.V., et al. (2019). A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia. Cancer Cell 36, 660-673 e611. 10.1016/j.ccell.2019.11.001.

Perner, F., et al. (2019). Roles of JAK2 in Aging, Inflammation, Hematopoiesis and Malignant Transformation. Cells 8. 10.3390/cells8080854.

Schubert, C. et al. (2019) Differential roles of STAT1 and STAT2 in the sensitivity of JAK2V617F- vs. BCR-ABLpositive cells to interferon alpha. J Hematol Oncol 12, 36. https://doi.org:10.1186/s13045-019-0722-9

Vorbach, S., et al. (2019). Enhanced expression of the sphingosine-1-phosphate-receptor-3 causes acute myelogenous leukemia in mice. Leukemia. 10.1038/s41375-019-0577-7.

Jutzi, J.S., et al. (2018). LSD1 Inhibition Prolongs Survival in Mouse Models of MPN by Selectively Targeting the Disease Clone. Hemasphere 2, e54. 10.1097/HS9.0000000000000054.

Mathew, N.R., et al. (2018). Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat Med 24, 282-291. 10.1038/nm.4484.

Prestipino, A., et al. (2018). Oncogenic JAK2(V617F) causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. Sci Transl Med 10. 10.1126/scitranslmed.aam7729.

Bogeska, R., et al. (2013). Elevated nuclear factor erythroid-2 levels promote epo-independent erythroid maturation and recapitulate the hematopoietic stem cell and common myeloid progenitor expansion observed in polycythemia vera patients. Stem Cells Transl Med 2, 112-117. 10.5966/sctm.2012-0046.

Damm, F., et al. (2014). Acquired initiating mutations in early hematopoietic cells of CLL patients. Cancer Discov 4, 1088-1101. 10.1158/2159-8290.CD-14-0104.

Dierks, C. (2010). GDC-0449–targeting the hedgehog signaling pathway. Recent Results Cancer Res 184, 235-238. 10.1007/978-3-642-01222-8_17.

Dierks, C., et al. (2010). The ITK-SYK fusion oncogene induces a T-cell lymphoproliferative disease in mice mimicking human disease. Cancer Res 70, 6193-6204. 10.1158/0008-5472.CAN-08-3719.

Dierks, C., et al. (2008). Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell 14, 238-249. 10.1016/j.ccr.2008.08.003.

Dierks, C., et al. (2007). Essential role of stromally induced hedgehog signaling in B-cell malignancies. Nat Med 13, 944-951. 10.1038/nm1614.

Fleischman, A.G., et al. (2011). TNFalpha facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. Blood 118, 6392-6398. 10.1182/blood-2011-04-348144.

Grundler, R., et al. (2009). Dissection of PIM serine/threonine kinases in FLT3-ITD-induced leukemogenesis reveals PIM1 as regulator of CXCL12-CXCR4-mediated homing and migration. J Exp Med 206, 1957-1970. 10.1084/jem.20082074

Heidel, F.H., et al. (2012). Genetic and pharmacologic inhibition of β-catenin targets imatinib-resistant leukemia stem cells in CML. Cell Stem Cell 10, 412-424. 10.1016/j.stem.2012.02.017.

Hofbauer, S. W. et al. (2016) The AKT1 isoform plays a dominant role in the survival and chemoresistance of chronic lymphocytic leukaemia cells. Br J Haematol 172, 815-819. https://doi.org:10.1111/bjh.13542

Hofbauer, S. W. et al. (2014) Tiam1/Rac1 signals contribute to the proliferation and chemoresistance, but not motility, of chronic lymphocytic leukemia cells. Blood 123, 2181-2188. https://doi.org:10.1182/blood-2013-08- 523563

Hockendorf, U., et al. (2016). RIPK3 Restricts Myeloid Leukemogenesis by Promoting Cell Death and Differentiation of Leukemia Initiating Cells. Cancer Cell 30, 75-91. 10.1016/j.ccell.2016.06.002.

Jutzi, J.S., et al. (2015). The Hen or the Egg: Inflammatory Aspects of Murine MPN Models. Mediators Inflamm 2015, 101987. 10.1155/2015/101987

Jutzi, J.S., et al. (2013). MPN patients harbor recurrent truncating mutations in transcription factor NF-E2. J Exp Med 210, 1003-1019. 10.1084/jem.20120521.

Kaufmann, K.B., et al. (2012). A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2. J. Exp. Med. 209, 35-50. 10.1084/jem.20110540.

Klein, C., et al. (2016). Ptch2 loss drives myeloproliferation and myeloproliferative neoplasm progression. J Exp Med 213, 273-290. 10.1084/jem.20150556.

Koschmieder, S., et al. (2016). Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both. Leukemia 30, 1018-1024. 10.1038/leu.2016.12.

Schnoder, T.M., et al. (2017). Cell autonomous expression of CXCL-10 in JAK2V617F-mutated MPN. J Cancer Res Clin Oncol 143, 807-820. 10.1007/s00432-017-2354-1.

Sprissler, C., et al. (2014). Depletion of STAT5 blocks TEL-SYK-induced APMF-type leukemia with myelofibrosis and myelodysplasia in mice. Blood Cancer J 4, e240. 10.1038/bcj.2014.53.

Wehrle, J., et al. (2013). Transcription factor nuclear factor erythroid-2 mediates expression of the cytokine interleukin 8, a known predictor of inferior outcome in patients with myeloproliferative neoplasms. Haematologica 98, 1073-1080. 10.3324/haematol.2012.071183.

Wilhelm, K., et al. (2010). Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R. Nat Med 16, 1434-1438. 10.1038/nm.2242.